Technical Trend Overview and Price Movement
As of 9 February 2026, Sun Pharma’s stock closed at ₹1,694.00, down 0.49% from the previous close of ₹1,702.30. The intraday range was relatively narrow, with a low of ₹1,690.00 and a high of ₹1,708.10. The stock remains comfortably above its 52-week low of ₹1,547.25 but has yet to reclaim its 52-week high of ₹1,850.95. This price action aligns with the broader technical assessment indicating a transition from a neutral sideways trend to a mildly bearish one.
Momentum Indicators: MACD and RSI Analysis
The Moving Average Convergence Divergence (MACD) indicator presents a bearish outlook on the weekly chart and a mildly bearish stance on the monthly chart. This suggests that while short-term momentum is weakening, the longer-term trend is only slightly negative, indicating potential caution among investors. The Relative Strength Index (RSI), however, remains neutral on both weekly and monthly timeframes, signalling no immediate overbought or oversold conditions. This lack of a definitive RSI signal implies that the stock is not currently exhibiting extreme momentum in either direction, reinforcing the mixed technical picture.
Moving Averages and Bollinger Bands
Daily moving averages provide a mildly bullish signal, suggesting that short-term price averages are still trending upwards, which could offer some support to the stock price. Conversely, Bollinger Bands indicate a mildly bearish trend on the weekly chart and a sideways pattern on the monthly chart. The weekly Bollinger Bands’ mild bearishness points to increased volatility and a potential downward pressure in the near term, while the monthly sideways pattern suggests consolidation over a longer horizon.
Additional Technical Signals: KST, Dow Theory, and OBV
The Know Sure Thing (KST) oscillator, a momentum indicator, aligns with the bearish narrative on both weekly and monthly charts, signalling mild bearishness. Dow Theory assessments echo this sentiment with a mildly bearish weekly outlook but no clear trend on the monthly scale. On-Balance Volume (OBV), which measures buying and selling pressure, also reflects a mildly bearish weekly trend, though it remains neutral monthly. Collectively, these indicators suggest that while selling pressure has increased recently, the longer-term volume trends have yet to confirm a decisive bearish reversal.
Comparative Performance Against Sensex
Sun Pharma’s returns relative to the Sensex reveal a mixed performance. Over the past week, the stock outperformed the benchmark with a 6.21% gain compared to Sensex’s 1.59%. However, over the one-month period, the stock declined by 3.76%, slightly worse than the Sensex’s 1.74% drop. Year-to-date, Sun Pharma’s return of -1.50% marginally outperforms the Sensex’s -1.92%. Over longer horizons, the stock has delivered robust gains, with a 3-year return of 65.51% versus Sensex’s 38.13%, and a 5-year return of 166.86% compared to 64.75% for the benchmark. The 10-year return, however, lags behind the Sensex at 97.71% against 239.52%, reflecting sector-specific challenges and market cycles.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Mojo Score and Grade Revision
Sun Pharmaceutical Industries Ltd currently holds a Mojo Score of 57.0, which corresponds to a Mojo Grade of Hold, downgraded from Buy on 19 January 2026. This revision reflects the recent technical deterioration and the cautious stance adopted by the MarketsMOJO analytical framework. The company’s Market Cap Grade remains at 1, indicating a large-cap status but with limited recent momentum. The downgrade signals that while the stock is not yet a sell, investors should exercise prudence and monitor for further technical developments before committing additional capital.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Sun Pharma faces sector-specific headwinds including regulatory scrutiny, pricing pressures, and competitive innovation cycles. The mildly bearish technical signals may partly reflect these broader challenges. However, the company’s long-term outperformance relative to the Sensex over three and five years underscores its resilience and capacity for value creation despite cyclical volatility.
Outlook and Investor Considerations
Given the mixed technical signals, investors should approach Sun Pharma with a balanced perspective. The mildly bearish weekly indicators caution against aggressive accumulation at current levels, while the neutral RSI and mildly bullish daily moving averages suggest potential for short-term support. Long-term investors may find comfort in the company’s historical returns and sector positioning but should remain vigilant for confirmation of trend reversals or further deterioration in momentum.
Summary of Technical Signals
In summary, the technical landscape for Sun Pharmaceutical Industries Ltd is characterised by:
- Weekly MACD and KST indicating mild bearishness
- Monthly MACD mildly bearish, with neutral RSI readings
- Daily moving averages mildly bullish, offering short-term support
- Bollinger Bands suggesting weekly mild bearishness and monthly sideways consolidation
- Dow Theory and OBV confirming mild bearishness on weekly charts but neutral monthly trends
This combination points to a cautious near-term outlook with potential for consolidation or modest declines, balanced by longer-term stability.
Holding Sun Pharmaceutical Industries Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion
Sun Pharmaceutical Industries Ltd’s recent technical parameter changes reflect a subtle shift towards a mildly bearish momentum, tempered by mixed signals across key indicators. While the downgrade to a Hold rating advises caution, the stock’s historical resilience and sector fundamentals provide a foundation for potential recovery. Investors should closely monitor weekly MACD and KST trends alongside price action near key moving averages to gauge the next directional move. A sustained breach below recent support levels could confirm a deeper bearish phase, whereas stabilisation above daily moving averages may signal renewed strength.
In the current environment, a measured approach combining technical analysis with fundamental insights will best serve investors seeking to navigate the evolving landscape of Sun Pharma’s stock performance.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
